TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00000439
Drug: sodium valproate
Normalized name: sodium valproate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subjects were randomized to sodium valproate vs placebo. Serum sodium valproate was monitored. This intervention was added on treatment as usual which was defined as being on lithium carbonate and also attending individual dual recovery counseling.
Study: NCT00006482
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006482
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02562313
Drug: BioChaperone insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: BioChaperone insulin lispro bolus infusion followed by test meal intake
Study: NCT00544596
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00544596
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00099983
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Initiate treatment with a low dose (1 mg/day HS) for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day. Escalation to a maximum of 4 mg/day will be allowed after a minimum of 4 weeks at the target dose (3 mg/day). Reduction to a lower dose will be allowed at any time, based on adverse effects. Treatment will continue for 6 months. Patients who discontinue treatment will be allowed to resume treatment at any time.
Study: NCT02641080
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, this could lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
Study: NCT00554762
Drug: GW842166X
DrugBank: GW842166 (DB11903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer
Study: NCT03569839
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients undergoing surgery, TIVA (total intravenous anaesthesia)
Study: NCT03492931
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive a single dose of ticagrelor
Study: NCT01107782
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg TDS orally until birth
Study: NCT02963701
Drug: Pseudoephedrine-HCl
Normalized name: Pseudoephedrine Hydrochloride
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed dose combination
Study: NCT02437370
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT02437370
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02437370
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01954316
Drug: CFI-400945
Normalized name: Cfi-400945 free base
DrugBank: Ocifisertib (DB18746)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polo-like kinase 4 (PLK4) inhibitor
Study: NCT03704181
Drug: Colchicine 0.5 MG twice day for one year
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo twice day for one year
Study: NCT00946673
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally up to 400 mg
Study: NCT00670228
Drug: Insulin Glargine (LANTUS)
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous insulin glargine was initiated 90 prior to the insulin glulisine infusion discontinuation (i.e. 48 hours after randomization) and titrated as per physician preference to maintain the plasma glucose between 90-130 mg/dL
Study: NCT01181258
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m\^2 administered intravenously (IV) weekly \* 4, (day -7, -1, +6, +13) pre-infusion with natural killer cells (NK)
Study: NCT01181258
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg/kg on Days -2 through +9 as an intravenous (IV) infusion.
Study: NCT01181258
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/m\^2/day administered as a 1 hour IV infusion once a day for 5 doses (day -6 through day -2).
Study: NCT00696969
Drug: Amphotericin B Deoxycholate
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg/kg e.o.d for 30 days
Study: NCT00696969
Drug: Ambisome + Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ambisome (i.v. single dose 5 mg/kg)+ Miltefosine 7 days
Study: NCT01462890
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg/m², iv on day 1 every 3 weeks for 6 cycles
Study: NCT01462890
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5, iv on day 1 every 3 weeks for 6 cycles
Study: NCT01624090
Drug: Mithramycin
Normalized name: Mithramycin
DrugBank: Plicamycin (DB06810)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mcg/kg intravenous (IV) over 6 hours once daily for 7 days, to be repeated every 21 days (one cycle) until disease progression or unacceptable toxicity
Study: NCT01379300
Drug: dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dabigatran etexilate, orally, as 2 x 75-mg capsules (150 mg), single administration
Study: NCT01379300
Drug: rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rivaroxaban, orally, as 2 x 10-mg tablets (20 mg), single administration
Study: NCT00651365
Drug: JNJ-38877605
Normalized name: JNJ-38877605
DrugBank: JNJ-38877605 (DB13113)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00752726
Drug: Orlistat
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weight loss treatment
Study: NCT01895309
Drug: Enbrel (etanercept)
Normalized name: etanercept Cartridge [Enbrel]
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01895309
Drug: SB4 (proposed biosimilar to etanercept)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02758327
Drug: TheraTears Lubricating Eye Drops
Normalized name: Soothe Lubricant Eye Drops
DrugBank: Povidone (DB11061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Carboxy-methylcellulose 0.25% eye Lubricant
Study: NCT00171847
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00171847
Drug: Trastuzumab plus Letrozole
Normalized name: Letrozole
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01332747
Drug: safoof e muhazzil
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~to be given in a dosage of 5 gms twice daily
Study: NCT01332747
Drug: compressed tablet of safoof e muhazzil
Normalized name: vitamin E Chewable Tablet
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~compressed into tablets of 1 gm each+ binders qs. dose is 5 tablets twice daily
Study: NCT01332747
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin 10 mgs once daily
Study: NCT00547521
Drug: abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: solution, subcutaneous injection, 125 mg/kg, weekly, 106 days in short term; long term is open
Study: NCT03875664
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended-release local anesthetic
Study: NCT00629473
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg oral or IV day before and day after NPI-0052 dosing.
Study: NCT03042260
Drug: Trimethoprim-Sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
Study: NCT00670228
Drug: Insulin Glulisine (Apidra)
Normalized name: insulin glulisine, human Injectable Solution [Apidra]
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prior PCI, subjects received a single IV bolus of insulin glulisine. The dose was 0.025 U/kg based upon patient reported weight.~Then IV insulin glulisine infusion was started within one hour of the IV insulin glulisine bolus and administered at a minimum rate of 2 U/h for 48 hours. The infusion was titrated in order to achieve and maintain the plasma glucose between 90 and 130 mg/dL.
Study: NCT03837899
Drug: Durvalumab / Tremelimumab Combination Therapy
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting dose:~durvalumab: 20mg/kg tremelimumab: 1mg/kg at cycles 2 to 5 only co-administered with durvalumab. The Recommended Phase 2 dose will be used for the dose expansion phase.
Study: NCT00528996
Drug: Tiotropium Bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution
Study: NCT02379468
Drug: Panthenol
Normalized name: Panthenol
DrugBank: Panthenol (DB11204)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment
Study: NCT02913768
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01089790
Drug: Dutogliptin
Normalized name: Dutogliptin
DrugBank: Dutogliptin (DB11723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg tablet, once daily
Study: NCT01089790
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg capsule (each capsule contains two 50-mg tablets), once daily
Study: NCT01243827
Drug: carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP \<140/90 mmHg.
Study: NCT01243827
Drug: bisoprolol
Normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP \<140/90 mmHg.
Study: NCT03879889
Drug: Nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Four weeks of nicotine patch will be provided at the first contact, which will be prescribed using the guidelines based on the subject's daily cigarette consumption. At week-4 visit, four more weeks of NRT will be provided.
Study: NCT00393939
Drug: Sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib 37.5 mg daily by oral capsule in schedule 2/1 with Docetaxel 75 mg/m2 every 3 weeks or 37. 5 mg daily in continuous dosing (in absence of docetaxel)
Study: NCT00393939
Drug: Taxotere
Normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m2 every 3 weeks in the comparator arm
Study: NCT01099436
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01882868
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: Concentrated solution (100 mg/4 mL \[25 mg/mL\], 200 mg/8 mL \[25 mg/mL\]) for infusion; Route of administration: Intravenous
Study: NCT01882868
Drug: Levofolinate
Normalized name: sodium levofolinate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
Study: NCT01882868
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
Study: NCT01882868
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
Study: NCT04465968
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 60 mg/m2, IV, day 1
Study: NCT04465968
Drug: S1
Normalized name: LS11
DrugBank: LS11 (DB05918)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 - 120 mg/day, PO, day 1-14
Study: NCT04465968
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: preoperative durvalumab therapy within 28 days after chemoradiotherapy. Two courses are given every two weeks.
Study: NCT04465968
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: (For resectable SST) Postoperative durvalumab therapy will be started between day 28 and day 63 with the day of surgery as Day 1. Twenty-two courses are given as a 2-week course.~Drug: Durvalumab 10 mg/kg/body, IV, day 1 (For unreectable SST) Additional durvalumab therapy between day 15 and day 28 of the second course of preoperative durvalumab therapy.~Twenty-two courses are given as 2-week course. Drug: Durvalumab 10 mg/kg/body, IV, day 1
Study: NCT04135014
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
Study: NCT04135014
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intranasal dexmedetomidine 2µg.kg-1 approximately 30-40 mins before surgery using a computer-generated random number table.
Study: NCT04135014
Drug: Midazolam and Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral midazolam 0.5mg.kg-1 and intranasal dexmedetomidine 1ug.kg-1 approximately 30-40 mins before surgery using a computer-generated random number table.
Study: NCT02081599
Drug: Teneli (Teneligliptin)
Normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Study: NCT02081599
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01586455
Drug: Human Placental Derived Stem Cell
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusions of thawed HPDSC to be given following UCB infusion.
Study: NCT03891914
Drug: Positron Emission Tomography using 18F-FCH
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FCH(or fluorocholine) for the detection of bone lesions
Study: NCT03891914
Drug: Positron Emission Tomography using 18F-FDG
Normalized name: (18F)-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FDG (or fluorodeoxyglucose) for the detection of bone lesions
Study: NCT02054884
Drug: Arm A: F16IL2 in combination with paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (i.v.) 1 hour infusions of paclitaxel 90 mg/m\^2 followed, after 30 min pause, by 3 hour i.v. infusions of F16IL2 35 Mio IU on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent.
Study: NCT02054884
Drug: Arm B: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (i.v.) 1 hour infusions of Paclitaxel 90 mg/m\^2 on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent.
Study: NCT01570049
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: for injection
Study: NCT03344627
Drug: Meropenem standard dose
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Empirical with 1 g meropenem intravenous infusion in 30 minutes then 1 g intravenous infusion in 3 hours every 8 hours.~* Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection.
Study: NCT03344627
Drug: Meropenem high dose
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Empirical with 2 g meropenem intravenous infusion in 30 minutes then 2 g intravenous infusion in 3 hours every 8 hours.~* Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection
Study: NCT02561130
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose is titrated to achieve fasting normoglycemia
Study: NCT02561130
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose is titrated to 1 g bid or maximal tolerated dose
Study: NCT02561130
Drug: Forxiga
Normalized name: Farxiga
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose is titrated to 10 mg po daily or maximal tolerated dose
Study: NCT01469065
Drug: PF-04991532
Normalized name: PF-04991532
DrugBank: PF-04991532 (DB11765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of PF-04991532; 25 mg given twice a day (BID) for 14 days
Study: NCT01469065
Drug: PF-04991532
Normalized name: PF-04991532
DrugBank: PF-04991532 (DB11765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of PF-04991532; 75 mg given twice a day (BID) for 14 days
Study: NCT01469065
Drug: PF-04991532
Normalized name: PF-04991532
DrugBank: PF-04991532 (DB11765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of PF-04991532; 150 mg given twice a day (BID) for 14 days
Study: NCT04051502
Drug: Method 1: Indocyanine green dye
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injection 4 mL of ICG dye directly into the fallopian tube (1 or more places is acceptable) only to the side where the adnexal mass is located
Study: NCT01469065
Drug: PF-0499132
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of PF-04991532; 300 mg given twice a day (BID) for 14 days
Study: NCT03917134
Drug: cephalosporin + Metronidazole Vaginal
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration of cephalosporin in doses of 2 grams administered intravenously before surgery and metronidazole vaginal ovules 500mg twice a day for 5 days after performing laparoscopic hysterectomy
Study: NCT04051502
Drug: Method 2: Indocyanine green dye
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1mL of ICG injected at each of the four sites: only to the side where the adnexal mass is located~* Dorsal side of the IP ligament~* Ventral side of the IP ligament~* Dorsal side of the utero-ovarian ligament~* Ventral side of the utero-ovarian ligament
Study: NCT04051502
Drug: Method 3: Indocyanine green dye
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injection of 2mL of ICG dye into the IP ligament pedicle after the adnexal mass has been removed. Only to the side where the adnexal mass is located
Study: NCT04051502
Drug: Method 3: Indocyanine green dye
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injection of 2mL of ICG dye into the IP ligament pedicle before the adnexal mass is removed.
Study: NCT03083691
Drug: Nivolumab, Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort 1: addition of ipilimumab in case of progression on nivolumab monotherapy.
Study: NCT03083691
Drug: Nivolumab, Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cohort 2: upfront combination therapy of nivolumab and ipilimumab for four cycles, followed by nivolumab monotherapy.
Study: NCT00006094
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01655147
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Type=exact number, unit=mg, number=1,000, form=tablet, route=oral. Abiraterone acetate administered on Day 1 of Period 1, and Day 14 of Period 2.
Study: NCT01655147
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=600, form=capsule, route=oral. Rifampicin administered on Days 8 to 13 of Period 2.